Abstract
RNAi-based therapeutics remains one of the most promising strategies for the effective cancer treatment due to its high target-specificity, precise mechanism of action, greater potency and reduced side effects. Although, tremendous progress and advances have been made in the past few years to develop nanotechnology-based efficient non-viral delivery systems, there are still many hurdles and challenges that must be conquered to achieve the target of clinically relevant formulation in terms of safety, specificity and efficacy.
Highlights
Cancer is the leading cause of death worldwide and according to WHO accounted for almost 8.2 million deaths in 2012 [1]
The availability of potent anti-cancer drugs in the clinic, by large, the use of these cytotoxic agents impose some limitations, such as the nonspecific distribution at the tumor site, which results in the insufficient penetration of such drugs into the tumor tissues [2]
Another important limitation associated with the use of cytotoxic agents is the development of multi-drug resistance (MDR) [4]
Summary
Cancer is the leading cause of death worldwide and according to WHO accounted for almost 8.2 million deaths in 2012 [1]. The nonselective action of these agents results in the damage to the normal healthy cells, causing extreme side effects to the body and further limits the dose or its frequency of dosing [3]. Another important limitation associated with the use of cytotoxic agents is the development of multi-drug resistance (MDR) [4]. All these cases, overall reduces the efficacy of chemotherapeutic compounds
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
